Cor Integrilin confirmatory trial necessary for PTCA approval, committee says.Page 2
Executive Summary
COR INTEGRILIN CONFIRMATORY TRIAL NECESSARY FOR APPROVAL of the glycoprotein IIb/IIIa inhibitor, FDA's Cardiovascular & Renal Drugs Advisory Committee concluded at its Feb. 28 meeting. The committee voted 6-2 that the IMPACT-II trial showed positive results for Integrilin as adjunctive therapy in patients undergoing PTCA for prevention of acute cardiac ischemic complications, but members unanimously agreed that the IMPACT-II trial alone is insufficient to show clinical benefit.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth